Occurrence of Secondary Malignancies in Chronic Myeloid Leukemia During Therapy with Imatinib Mesylate-Single Institution Experience

INTRODUCTION: Imatinib mesylate (IM) remains the treatment of choice for chronic myeloid leukemia (CML) showing a remarkable efficacy and offers a perspective for long disease-free survival. Due to prolonged administration of IM, the questions about the possible impact on the development of secondar...

Descripción completa

Detalles Bibliográficos
Autores principales: Helbig, Grzegorz, Bober, Grażyna, Seweryn, Marek, Wichary, Ryszard, Tukiendorf, Andrzej, Sedlak, Lech, Oleksy, Tomasz, Kyrcz-Krzemień, Sławomira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283924/
https://www.ncbi.nlm.nih.gov/pubmed/25574362
http://dx.doi.org/10.4084/MJHID.2015.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283924/
https://www.ncbi.nlm.nih.gov/pubmed/25574362
http://dx.doi.org/10.4084/MJHID.2015.003

Ejemplares similares